Table 2.
Patient number | Age/sex | Malignancy | Radiation dose (cGy) | Time in months | Number of screws | Adjunct fixation | HHS | |||
---|---|---|---|---|---|---|---|---|---|---|
RAD to THA | Clinical followup‡ | Radiographic followup | Preoperative | 5-year | ||||||
1 | 69/male | Prostate | 7020 | 63 | 79 | 55 | 2 | None | 19 | 60 |
2 | 76/female | Cervical | > 4500 | 461 | 65 | 65 | 3 | None | 36 | 85 |
3 | 70/female | Uterine | 4530 | 87 | 93 | 63 | 4 | None | 24 | 87 |
4 | 70/female | Uterine | 4530 | 88 | 92 | 62 | 4 | None | 24 | 93 |
5 | 61/female | Colon | 5040 | 48 | 93 | 93 | 3 | None | 32 | 79 |
6 | 61/female | Colon | 5040 | 58 | 83 | 83 | 3 | None | 32 | 79 |
7 | 61/female | Ovarian | > 4500 | 61 | 112 | 112 | 2 | None | 36 | 86 |
8 | 61/female | Ovarian | > 4500 | 58 | 116 | 116 | 3 | None | 35 | 84 |
9 | 75/female | Ovarian | > 4500 | 800 | 116 | 62 | 3 | None | 20 | 81 |
10 | 71/male | Rectal | 5300 | 50 | 95 | 95 | 3 | None | 40 | 82 |
11 | 72/male | Anal | 5580 | 35 | 61 | 68 | 8 | Cup cage | 24 | 77 |
12 | 79/male | Prostate | 7200 | 20 | 57 | 55 | 6 | None | 39 | 79 |
13 | 79/male | Prostate | 7200 | 12 | 65 | 63 | 5 | None | 43 | 70 |
14 | 75/male | Prostate | > 4500 | 43 | 61 | 61 | 2 | None | 35 | 64 |
15 | 73/male | Prostate | 7200 | 44 | 64 | 88 | 0 | None | 33 | 83 |
16 | 80/male | Prostate | 6800 | 2 | 67 | 67 | 0 | None | 43 | 83 |
17 | 65/male | Prostate | 6000 | 41 | 74 | 74 | 2 | None | 45 | 81 |
18 | 66/male | Prostate | 6000 | 56 | 60 | 60 | 0 | None | 63 | 100 |
19 | 70/male | Lymphoma | > 4500 | 139 | 67 | 65 | 7 | Cup cage | 55 | 69 |
20 | 80/male | Myeloma | 4500 | 13 | 77 | 77 | 7 | Cup cage | NA | NA |
21 | 74/male* | Prostate | 6800 | 113 | 61 (67) | 61 | 3 | None | 35 | 84 |
22 | 77/male* | Prostate | 7380 | 4 | 64 (83) | 64 | 4 | None | 45 | 69 |
23 | 68/female*† | Uterine | > 4500 | 102 | 3 (6) | 3 | 3 | None | 23 | NA |
24 | 77/male*† | Prostate | > 4500 | 49 | 2 (38) | 0 | 3 | None | 27 | NA |
25 | 75/male*† | Prostate | 6400 | 125 | 35 (51) | 12 | 3 | None | 14 | NA |
26 | 72/male*† | Prostate | > 4500 | 80 | 28 (39) | 2 | 7 | None | 37 | NA |
27 | 58/female*† | Myeloma | > 4500 | 3 | 49 (58) | 13 | 6 | Augment | 22 | NA |
28 | 57/female*† | Myeloma | 15000 | 1 | 8 (12) | 2 | 4 | Femoral head | NA | NA |
29 | 76/male*† | Prostate | 7560 | 8 | 29 (30) | 26 | 4 | None | 21 | NA |
30 | 76/female*† | Anal | > 4500 | 89 | 21 (64) | 55 | 2 | None | 58 | NA |
31 | 64/female*† | Myeloma | 4000 | 134 | 70 (70) | 1 | 7 | Augment | 9 | 28 |
32 | 78/male*† | Prostate | > 4500 | 10 | 28 (62) | 28 | 2 | None | 26 | NA |
33 | 75/male*† | Prostate | > 4500 | 89 | 28 (49) | 2 | 4 | None | 20 | NA |
34 | 89/male*† | Prostate | > 4500 | 95 | 26 (38) | 29 | 6 | None | 29 | NA |
* Patient died.
†Patient excluded.
‡Numbers in parentheses indicate time from surgery to death.
HHS = Harris hip score; NA = not available.